Extensions

Patent Term Adjustments (PTA)

Patent Term Adjustment (PTA) extends the term of a U.S. patent to compensate for certain administrative delays by the USPTO during the patent prosecution process. These delays are categorized into specific timeframes, such as issuing an office action within 14 months of filing, responding to a reply within four months, and issuing a patent within 36 months from the filing date. The total PTA is added to the standard 20-year lifespan of the patent.

The provided information for US patent 11,419,823 does not explicitly state the calculated patent term adjustment. To determine the exact PTA, one would typically need to review the "Patent Term Adjustment" section in the patent's file wrapper on the USPTO Patent Center.

Patent Term Extensions (PTE)

Patent Term Extension (PTE) is distinct from PTA and is granted to compensate for delays in obtaining regulatory approval for products, most commonly drugs. For pharmaceutical patents, PTE aims to restore some of the patent term lost during the FDA approval process.

The provided patent text and search results do not explicitly mention whether US patent 11,419,823 has been granted a Patent Term Extension. This information would typically be found in the regulatory approval records associated with tacrolimus products covered by this patent.

Continuation and Divisional Applications

The provided patent description explicitly states that US patent 11,419,823 is part of a family of related applications:

• "The present application is a continuation of U.S. patent application Ser. No. 15/405,879, filed Jan. 13, 2017".
• "which is a continuation of U.S. patent application Ser. No. 13/029,304, filed Feb. 17, 2011".
• "which (i) claims the benefit of Danish Patent Application No. PA 2010-00137 filed Feb. 17, 2010, and U.S. Provisional Application No. 61/305,941, filed Feb. 18, 2010, and (ii) is a continuation-in-part of U.S. patent application Ser. No. 12/499,034, filed Jul. 7, 2009".
• "which (a) is a continuation-in-part of International Application No. PCT/DK2008/050130, filed May 30, 2008".

Therefore, US patent 11,419,823 is a continuation application of U.S. patent application Ser. No. 15/405,879, which itself is a continuation of Ser. No. 13/029,304. This chain of applications also includes a continuation-in-part relationship with Ser. No. 12/499,034, and ultimately traces back to PCT/DK2008/050130, filed May 30, 2008, and related provisional and Danish applications.

The provided information does not explicitly list any divisional applications directly stemming from US patent 11,419,823 itself.

Related Family Members

Based on the continuation chain described above, the following are related family members:

• U.S. patent application Ser. No. 15/405,879, filed Jan. 13, 2017
• U.S. patent application Ser. No. 13/029,304, filed Feb. 17, 2011
• U.S. patent application Ser. No. 12/499,034, filed Jul. 7, 2009
• International Application No. PCT/DK2008/050130, filed May 30, 2008
• Danish Patent Application No. PA 2010-00137, filed Feb. 17, 2010
• U.S. Provisional Application No. 61/305,941, filed Feb. 18, 2010

Additionally, US20190282504A1 is a publication related to the patent.

Projected Expiration Date

The Google Patents entry for US patent 11,419,823 states the "Anticipated expiration" date as 2028-05-30.

For applications filed on or after June 8, 1995, the patent term is generally 20 years from the date of the earliest related application, or the filing date if there are no earlier applications. Given that the earliest priority date for US 11,419,823 is May 30, 2008 (from PCT/DK2008/050130), a 20-year term from this date would indeed lead to an expiration date around May 30, 2028. This anticipated expiration date would include any Patent Term Adjustments that may have been granted.